Vinflunine
Javlor (vinflunine) is a small molecule pharmaceutical. Vinflunine was first approved as Javlor on 2009-09-21. It has been approved in Europe to treat transitional cell carcinoma and urologic neoplasms.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| urogenital diseases | D000091642 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
32 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urinary bladder neoplasms | D001749 | C67 | 2 | 4 | 4 | — | — | 8 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 2 | 4 | — | — | 6 |
| Transitional cell carcinoma | D002295 | — | 4 | 2 | — | — | 5 | ||
| Ureteral neoplasms | D014516 | EFO_0003844 | C66 | 1 | 2 | 1 | — | — | 4 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | 2 | — | — | 2 | |
| Head and neck neoplasms | D006258 | — | — | 1 | — | — | 1 | ||
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung neoplasms | D008175 | C34.90 | — | 2 | — | — | — | 2 | |
| Urologic neoplasms | D014571 | C64-C68 | 1 | 1 | — | — | — | 2 | |
| Urethral neoplasms | D014523 | EFO_0003846 | 1 | 1 | — | — | — | 2 | |
| Pelvic neoplasms | D010386 | 1 | 1 | — | — | — | 2 | ||
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | 1 | — | — | — | 1 |
| Penile neoplasms | D010412 | C60 | — | 1 | — | — | — | 1 | |
| Prostatic neoplasms | D011471 | C61 | — | 1 | — | — | — | 1 | |
| Small cell carcinoma | D018288 | — | 1 | — | — | — | 1 | ||
| Non-small-cell lung carcinoma | D002289 | — | 1 | — | — | — | 1 | ||
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | — | 1 | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | VINFLUNINE |
| INN | vinflunine |
| Description | Vinflunine (INN, trade name Javlor) is a novel fluorinated vinca alkaloid derivative undergoing research for the treatment of bladder cancer. It was originally discovered by the team of the Professor Jean-Claude Jacquesy (UMR CNRS 6514 – Poitiers University), developed by Laboratoires Pierre Fabre and was licensed to Bristol-Myers Squibb for development in certain countries, including the United States.
|
| Classification | Small molecule |
| Drug class | vinca alkaloids |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32 |
Identifiers
| PDB | — |
| CAS-ID | 162652-95-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2110725 |
| ChEBI ID | 90241 |
| PubChem CID | 6918295 |
| DrugBank | DB11641 |
| UNII ID | 5BF646324K (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,076 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
39,516 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more